The Endpoints poll: A large majority of biopharma execs turn thumbs down on Biogen's controversial pitch for aducanumab
There’s a big vote looming at the end of the week as outside experts at the FDA put Biogen’s Alzheimer’s drug aducanumab on trial. But as far as the industry is concerned, most people in biopharma have already made up their minds. And they’re turning thumbs down on that drug in large numbers.
More than a thousand people took our snap poll on the panel decision coming on Friday, and 63% of them say the panel will vote to reject Biogen’s bid to gain an approval on mixed data from two late-stage studies.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 117,600+ biopharma pros reading Endpoints daily — and it's free.